文献速递头颈部肿瘤放疗

局部晚期鼻咽癌VMAT与螺旋断层放疗疗效比较的倾向性评分匹配回顾性队列研究

Comparative effectiveness of Volumetric Modulated Arc Therapy versus tomotherapy in locally advanced nasopharyngeal carcinoma: a propensity score-matched retrospective cohort study.
PubMed 文献 · Radiat Oncol · 2026-03-02

中位随访42个月,两组3年OS、PFS、LRFS、DMFS及总缓解率均无显著差异;TOMO组口干发生率显著更低(33.86% vs 46.84%,P<0.001),其他不良事件组间无显著差异。结论为两种技术在局部晚期鼻咽癌中疗效相当。

要点

  • 匹配后两组3年OS、PFS、LRFS、DMFS及ORR均无显著差异。
  • TOMO组口干发生率显著低于VMAT组(33.86% vs 46.84%,P<0.001)。
  • 技术选择应基于机构条件与患者因素,而非预期生存获益。

核心结论

  • VMAT与TOMO在局部晚期鼻咽癌患者中产生相当的疗效。
  • 两种先进放疗技术均为多学科综合治疗中的有效选择。
  • 技术选择应基于机构能力和患者特异性因素,包括生活质量需求和靶区解剖,而非预期生存获益。

研究设计与样本

  • 患者接受VMAT(n=1720)或TOMO(n=254)联合按机构方案的系统治疗。
  • 采用1:1比例、最近邻匹配无放回、0.2个标准差卡钳的倾向性评分匹配以减少选择偏倚。
  • 匹配后979例纳入最终分析(VMAT 728例,TOMO 251例),所有基线变量SMD<0.1。
  • 主要终点为OS、PFS、LRFS、DMFS,次要终点为治疗缓解率和治疗相关不良事件。

主要发现

  • 中位随访42个月,3年OS在VMAT组为85.2%、TOMO组为87.1%(P=0.645)。
  • 3年PFS在VMAT组为78.9%、TOMO组为81.2%(P=0.391)。
  • 3年LRFS在VMAT组为91.3%、TOMO组为93.1%(P=0.505)。
  • 3年DMFS在VMAT组为85.7%、TOMO组为87.4%(P=0.383)。
  • 总缓解率在VMAT组为96.7%、TOMO组为97.6%(P=0.418);口干发生率TOMO组33.86%显著低于VMAT组46.84%(P<0.001),其他不良事件组间无显著差异。

临床怎么用

  • 局部晚期鼻咽癌选择VMAT或TOMO时可预期相似的生存和肿瘤控制结局。
  • 若更关注口干等生活质量相关毒性,TOMO可能因腮腺保护优势而成为考虑选项。
  • 技术选择应结合机构设备能力、靶区解剖特点和患者生活质量需求综合决定。

局限性

  • 本研究为单中心回顾性队列研究,可能存在残余混杂。
  • 匹配后TOMO组样本量(251例)明显小于VMAT组(728例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nasopharyngeal carcinoma (NPC) remains a major healthcare burden in endemic regions, and locally advanced disease demands optimal radiotherapy for curative intent. Although both Volumetric Modulated Arc Therapy (VMAT) and tomotherapy (TOMO) are both advanced conformal radiotherapy techniques, their comparative efficacy in locally advanced NPC has not been fully clarified by large-scale studies that adequately control for selection bias. This study compared the therapeutic efficacy and safety of VMAT versus TOMO in patients with locally advanced NPC. METHODS: We performed a retrospective cohort study of 1,974 patients with histologically confirmed locally advanced NPC treated at our institution between January 2016 and December 2019. Patients received either VMAT (n = 1,720) or TOMO (n = 254) combined with systemic therapy per institutional protocols. To reduce selection bias, propensity score matching (PSM) was conducted at a 1:1 ratio using nearest-neighbor matching without replacement, with a 0.2 standard deviation caliper to balance baseline characteristics between groups. Primary endpoints included overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS). The secondary endpoints were treatment response rates and treatment-related adverse events. RESULTS: After PSM, 979 patients were included in the final analysis (728 VMAT and 251 TOMO). Standardized mean differences (SMDs) for all baseline variables were < 0.1, confirming adequate balance between groups. With a median follow-up of 42 months, no significant differences in the 3-year survival rates were observed between the VMAT and TOMO groups: OS (85.2% vs. 87.1%, P = 0.645), PFS (78.9% vs. 81.2%,P = 0.391), LRFS (91.3% vs. 93.1%, P = 0.505), and DMFS (85.7% vs. 87.4%, P = 0.383). Both techniques achieved high overall response rates (ORR) (96.7% vs. 97.6%, p = 0.418). For safety, xerostomia occurred significantly less frequently in the TOMO group (33.86% vs. 46.84%, p < 0.001), consistent with its superior ability to spare parotid glands, while other adverse events showed no significant intergroup differences. CONCLUSIONS: VMAT and TOMO yield comparable therapeutic efficacies in patients with locally advanced NPC. Both advanced radiotherapy techniques are effective options in multimodality care. The choice between them should be based on institutional capacity and patient-specific factors, including quality-of-life needs and target volume anatomy, rather than anticipated survival benefits.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen Z, Huang Z, Cai S, et al. Comparative effectiveness of Volumetric Modulated Arc Therapy versus tomotherapy in locally advanced nasopharyngeal carcinoma: a propensity score-matched retrospective cohort study. Radiat Oncol. 2026. PMID: 41772627. doi:10.1186/s13014-026-02803-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。